US 11229702
High concentration formulations of adalimumab
granted A61KA61K39/39591
Quick answer
US patent 11229702 (High concentration formulations of adalimumab) held by Coherus BioSciences, Inc. expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Coherus BioSciences, Inc.
- Grant date
- Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K39/39591